China-based WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufacturing.
By combining advanced real-time process monitoring with Raman-based Process Analytical Technology (PAT) and predictive in-silico modeling, PatroLab™ enables real-time and smarter analytics, proactive control, and accelerated decision-making.
This integrated digital solution helps enhance process performance, minimise process risks, shorten development timelines, and ensure consistent, high-quality biologics manufacturing. With PatroLab™, WuXi Biologics sets a new benchmark for efficiency and reliability, enabling global clients to achieve faster time-to-market and robust commercial supply.
Central to the PatroLabTM platform is WuXi Biologics' advanced Raman PAT system, which marks a groundbreaking transition from conventional static, off-line testing to real-time, non-invasive monitoring of more than 40 key process performance and product quality attributes. This innovation enables deeper process insights and faster data-driven decisions.
By increasing data density per batch by nearly 1,000 times compared to traditional methods, PatroLabTM empowers clients to apply QbD (Quality by Design) principles more effectively, and accelerate bioprocess development and manufacturing – all while ensuring product quality and operational excellence.
Building on its real-time monitoring capability, the PatroLabTM platform combines data-driven and mechanistic modeling approaches with digital twin concepts to create virtual bioprocess replicas. This enables a transition from reactive responses to predictive decision-making.
